Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
Authors:
Open Access
- 11 October 2021
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 35 (11) , 1189-1205
Abstract
Schizophrenia is a serious mental illness that requires continuous and effective long-term management to reduce symptoms, improve quality of life, and prevent relapse. Oral antipsychotic medications have proven efficacy for many patients taking these medications; however, a considerable number of patients continue to experience ongoing symptoms and relapse, often due to lack of adherence. The advent of long-acting injectable (LAI) formulations of antipsychotic medications provided an opportunity to improve treatment adherence and overall patient outcomes. Despite data to support LAI efficacy, safety, and improved adherence over oral formulations, there are several misconceptions about and barriers to LAI implementation within a standard of care for patients with schizophrenia. Areas of resistance around LAIs include (1) doubts regarding their benefits outside of improved adherence, (2) questions regarding their prescribing to a broader population of patients with schizophrenia, (3) when to initiate LAIs, (4) concerns regarding the safety of LAIs in comparison with oral medication, and (5) the most effective ways to educate healthcare providers, patients, and caretakers to enable appropriate LAI consideration and acceptance. Here, we discuss these key controversies associated with LAIs and provide supportive evidence to facilitate LAI use in a manner that is constructive to the clinician–patient relationship and successful treatment.Keywords
Funding Information
- Teva Pharmaceutical Industries
This publication has 92 references indexed in Scilit:
- Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illnessBMC Psychiatry, 2013
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry, 2013
- Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesBMC Psychiatry, 2013
- The nature of relapse in schizophreniaBMC Psychiatry, 2013
- Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature reviewTherapeutic Advances in Psychopharmacology, 2013
- Adherence to oral second‐generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claimsInternational Journal Of Clinical Practice, 2012
- Opinions of French patients with schizophrenia regarding injectable medicationPatient Preference and Adherence, 2011
- Barriers to, and Strategies for, Starting a Long Acting Injection Clinic in a Community Mental Health CenterCommunity Mental Health Journal, 2011
- Financial incentives for antipsychotic depot medication: ethical issues: Table 1Journal of Medical Ethics, 2007
- Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or RisperidoneSchizophrenia Bulletin, 2006